Table 2: Antiphospholipid antibodies and LA in a relationship to arterial thrombosis (AT), venous thrombosis (VT), and obstetric complications (OC).

AntibodyArterial thrombosis (41)
No. valueOdds ratio (95% Cl)Sensitivity %Specificity %

LA170.431.4 (0.6–2.9)4959
aCLIgG34<0.0015.5 (2.3–13.4)8353
IgM60.671.2 (0.4–3.5)1588
Anti- GPIIgG260.022.4 (1.2–5.1)6358
IgM50.991.0 (0.3–2.9)1288
In-house aPS/PTIgG180.081.9 (0.9–4.1)4471
IgM160.361.4 (0.6–2.9)3969
QUANTA Lite aPS/PTIgG170.032.3 (1.0–4.9)4177
IgM170.381.4 (0.7–2.9)4166
LAC260.501.3 (0.6–2.7)6243

Venous thrombosis (53)
LA31<0.0015.6 (2.6–12.2)7070
aCLIgG39<0.0053.0 (1.5–6.2)7452
IgM120.0103.5 (1.3–9.2)2392
Anti- GPIIgG35<0.0013.2 (1.6–6.5)6663
IgM100.0702.5 (0.9–6.5)1991
In-house aPS/PTIgG27<0.0013.5 (1.7–7.0)5177
IgM240.0212.2 (1.1–4.5)4573
QUANTA Lite aPS/PTIgG25<0.0014.0 (1.9–8.3)4782
IgM260.0132.4 (1.2–4.7)4971
LAC370.0432.1 (1.0–4.2)7047

Obstetric complications (28)
LA13<0.0054.3 (1.6–11.9)6273
aCLIgG22<0.0015.8 (2.1–15.9)7961
IgM60.1302.5 (0.8–7.8)2190
Anti- GPIIgG190.0024.1 (1.7–10.4)6866
IgM50.2782.0 (0.6–6.6)1890
In-house aPS/PTIgG18<0.0019.3 (3.5–24.6)6484
IgM15<0.0054.0 (1.6–9.9)5478
QUANTA Lite aPS/PTIgG14<0.0016.3 (2.4–16.7)5086
IgM16<0.0054.3 (1.7–10.6)5776
LAC210.0422.7 (1.0–9.1)7548

aCL: anticardiolipin, anti- GPI: anti- glycoprotein, aPS/PT: anti-phosphatidylserine/prothrombin, LA: lupus anticoagulant, OR: odds ratio, and CI: confidence interval.